The 5α-Reductase Inhibitor Dutasteride but Not Finasteride Protects Dopamine Neurons in the MPTP Mouse Model of Parkinson’s Disease

May 2015 in “ Neuropharmacology ”

Nadhir Litim, Mélanie Bourque, Sara Al Sweidi, Marc Morissette, Thérèse Di Paolo

Dutasteride 5α-reductase inhibitor Finasteride dopamine neurons plasma testosterone Avodart Propecia testosterone

From the encyclopedia

Dutasteride →

Heavy duty finasteride that comes with higher risks

Finasteride →

Frontline, gold standard treatment for combatting androgenic alopecia

Studysummary This study found that Dutasteride, a 5α-reductase inhibitor, demonstrated neuroprotective effects by preventing the MPTP-induced decline of dopaminergic markers in a Parkinson's disease mouse model.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study found that Dutasteride, a 5α-reductase inhibitor, protected dopamine neurons in a mouse model of Parkinson's disease, while Finasteride had no effect. Dutasteride prevented the loss of dopamine uptake and storage, and also prevented the decrease in plasma testosterone levels induced by MPTP. The study suggests that Dutasteride may have potential as a treatment for Parkinson's disease.

View this study on sciencedirect.com →

Discuss this study in the Community →

Research cited in this study

9 / 9 results

research Inhibition Of 5α-Reductase Attenuates Behavioral Effects Of D1-, But Not D2-Like Receptor Agonists In C57BL/6 Mice

42 citations , August 2012 in “Psychoneuroendocrinology”

Finasteride reduces certain behaviors caused by D1-like receptor agonists but not by D2-like receptor agonists in mice.

research Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders

72 citations , January 2011 in “Current Pharmaceutical Design”

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

research A Connection Between the Mitochondrial Permeability Transition Pore, Autophagy, and Cerebral Amyloidogenesis

14 citations , May 2008 in “Journal of proteome research”

This study found that dutasteride reduced β-amyloid plaque load in a cerebral amyloidosis model, seemingly linked to mitochondrial apoptosis and autophagy processes.

research Antipsychotic-Like Properties of 5-Alpha-Reductase Inhibitors

64 citations , March 2008 in “Neuropsychopharmacology”

research A New Look at the 5-Alpha-Reductase Inhibitor Finasteride

137 citations , March 2006 in “Cns Drug Reviews”

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

408 citations , May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

research Inhibition of Rat Alpha-Reductases by Finasteride: Evidence for Isozyme Differences in the Mechanism of Inhibition

98 citations , April 1997 in “The Journal of Steroid Biochemistry and Molecular Biology”

Finasteride effectively blocks rat enzymes, but with varying methods and strength.

Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor

research Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor

136 citations , March 1996 in “Journal of the American Chemical Society”

This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.

research Four-Amino Acid Segment in Steroid 5 Alpha-Reductase 1 Confers Sensitivity to Finasteride, a Competitive Inhibitor

83 citations , April 1992 in “Journal of Biological Chemistry”

Four-amino acid part makes enzyme sensitive to finasteride.